The tumours in infants differ from older children in clinical presentation, biological characteristics and response to therapy. The therapy may be impaired by concerns about increased adverse effects due to chemotherapy and radiotherapy. Many of the tumours are related to disruption of normal embryonic development, and as such, embryonal tumours are more common. This presentation will give an overview of rare solid tumours that occur in infancy, and review the use of molecular studies for accurate diagnosis and targeted therapies for their treatment.
Rajkumar Venkatramani, MD, MS, FAAP
Associate Professor Department of Pediatrics
Baylor College of Medicine, Houston, TX
Texas Children’s Cancer Center, Texas Children’s Hospital, Houston, TX
Dr. Venkatramani completed his pediatric training at King’s College in London, and obtained membership in the Royal College of Paediatrics and Child Health. He completed a fellowship in pediatric hematology oncology at Children’s Hospital, Los Angeles. He is currently the director of the Rare Tumors Program and Thyroid Cancer Program at Texas Children’s Hospital in Houston, Texas. He is the author of more than 50 original publications, multiple reviews and book chapters, and is a member of the Pediatric Blood and Cancer editorial board and PREP Hematology/Oncology editorial board.